BiotechTube

OPT-80 + vancomycin

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile

Conditions

Clostridium Difficile

Trial Timeline

Jun 23, 2014 → Sep 8, 2016

NCT ID
NCT02179658

About OPT-80 + vancomycin

OPT-80 + vancomycin is a phase 3 stage product being developed by Astellas Pharma for Clostridium Difficile. The current trial status is completed. This product is registered under clinical trial identifier NCT02179658. Target conditions include Clostridium Difficile.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02179658Phase 3Completed

Competing Products

20 competing products in Clostridium Difficile

See all competitors
ProductCompanyStageHype Score
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
85
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
23
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
77
Fidaxomicin + VancomycinAstellas PharmaApproved
85
Fidaxomicin + VancomycinMerckApproved
85
fidaxomicin + PlaceboMerckPhase 3
77
Surotomycin + PlaceboMerckPhase 1
33
CB-183,315 + Placebo + VancomycinMerckPhase 2
52
Surotomycin + PlaceboMerckPhase 1
33
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
77
Vancomycin + FidaxomicinMerckApproved
85
FidaxomicinMerckPre-clinical
23
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
23
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
77
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
77
bezlotoxumab + Vancomycin OralMerckApproved
85
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
77
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
23
PAR-101/OPT-80 + VancomycinMerckPhase 3
77
fidaxomicinMerckPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85